Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...
A major challenge for mRNA-based vaccines and therapeutics is the limited stability of mRNA in vivo. Viruses offer a promising source of RNA-stabilizing elements, but those identified so far are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results